Analysts Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) PT at $32.60

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) have received an average recommendation of “Hold” from the six analysts that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $32.60.

A number of brokerages recently commented on SLN. Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Wednesday, October 8th. Wall Street Zen raised shares of Silence Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th.

Silence Therapeutics Trading Up 3.2%

Silence Therapeutics stock opened at $5.20 on Friday. The firm has a 50-day moving average of $6.25 and a 200-day moving average of $5.95. The firm has a market cap of $245.60 million, a P/E ratio of -3.85 and a beta of 1.32. Silence Therapeutics has a 1-year low of $1.97 and a 1-year high of $7.78.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05). Silence Therapeutics had a negative net margin of 254.25% and a negative return on equity of 61.76%. The business had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $3.28 million. Research analysts forecast that Silence Therapeutics will post -1.77 earnings per share for the current fiscal year.

Institutional Trading of Silence Therapeutics

Several large investors have recently bought and sold shares of SLN. Boothbay Fund Management LLC raised its position in shares of Silence Therapeutics by 1.0% in the 2nd quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock worth $1,464,000 after acquiring an additional 2,409 shares in the last quarter. Two Sigma Investments LP grew its stake in Silence Therapeutics by 6.6% in the third quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock worth $328,000 after purchasing an additional 3,935 shares during the period. GAMMA Investing LLC raised its holdings in Silence Therapeutics by 134.1% in the second quarter. GAMMA Investing LLC now owns 8,333 shares of the company’s stock worth $48,000 after purchasing an additional 4,773 shares in the last quarter. EHP Funds Inc. purchased a new position in Silence Therapeutics during the third quarter valued at $55,000. Finally, Beacon Pointe Advisors LLC bought a new stake in shares of Silence Therapeutics during the 2nd quarter valued at $67,000. 98.73% of the stock is owned by institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.